Doxorubicin

• A Study of an experimental drug, MK-2140 in combination with standard of care chemotherapy in participants with Diffuse Large B-Cell Lymphom… Ended
  2022-501380-40-00 Phase II 3 countries Merck Sharp & Dohme LLC
• A Randomized Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults … Ended
  2023-503640-14-00 Phase III 17 countries Amgen Inc.
• VERLEN - Phase II, Open-Label Study evaluating efficacy of Lenalidomide and Tafasitamab combination associated to Rituximab in frontline Dif… Ended
  2023-507286-25-00 Phase II 2 countries LYSARC
• DESTINY-Breast11 will compare trastuzumab deruxtecan (T-DXd) alone or in sequence with other medications, known as THP, with standard of car… Ended
  2023-505210-18-00 Phase III 4 countries AstraZeneca AB
• Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden Follicular Lymph… Ended
  2024-511636-27-00 Phase III 1 country Fondazione Italiana Linfomi Ets
• Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic… Ended
  2023-506752-24-00 Phase III 13 countries Merck Sharp & Dohme LLC
• A Combination of Acalabrutinib with R-CHOP in Subjects with previously untreated non-GCB DLBCL Ended
  2023-509358-72-00 Phase III 9 countries Acerta Pharma B.V.
• A phase II trial of MK-3475 (pembrolizumab) in children and young adults with classical Hodgkin lymphoma Ended
  2023-504821-38-00 Phase II 8 countries Merck Sharp & Dohme LLC
• A Phase II study of post-operative palbociclib as an alternative to chemotherapy in older patients with localized breast cancer at high risk… Ended
  2023-505223-31-00 Phase II 7 countries European Organisation For Research And Treatment Of Cancer
• Phase III study of pembrolizumab for high-risk early-stage ER+/HER2– breast cancer Ended
  2023-506921-12-00 Phase III 8 countries Merck Sharp & Dohme LLC
• B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and… Ended
  2023-505509-18-00 Phase III 7 countries Universitaetsklinikum Muenster AöR
• A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL… Ended
  2024-515846-18-00 Phase I (FiH) 2 countries LYSARC
• HOVON 127 BL / SAKK 37/16: Phase III study comparing 2 treatments (R-CODOX-M/R-IVAC versus DA-EPOCH-R) in patients with Burkitt lymphoma Ended
  2023-503423-25-00 Phase III 2 countries Haemato Oncology Foundation For Adults Netherlands
• "A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone… Ended
  2024-515368-29-00 Phase III 1 country Fundacion Grupo Espanol De Investigacion En Cancer De Mama
• Chemotherapy or chemotherapy + hormonotherapy in women over 70 with HER2 receptor-negative but estrogen receptor-positive breast cancer acco… Ended
  2024-516996-34-00 Phase III 2 countries Unicancer
• Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcomas Ended
  2024-510877-67-00 1 country Asoc Grupo Espanol De Investigacion En Sarcomas
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended
  2022-501260-18-00 Phase II 7 countries Kite Pharma Inc.
• Phase 2 study of pembrolizumab and chemotherapy in participants with classical Hodgkin Lymphoma that has just been diagnosed Ended
  2022-501615-14-00 Phase II 4 countries Merck Sharp & Dohme LLC
• ABCSG 45: A clinical trial that examines whether the treatment with the medication olaparib in combination with the chemotherapy carboplatin… Ended
  2024-512821-10-00 Phase II 1 country Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And…

Showing 25–43 of 43 trials